Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Medical treatment of non-small-cell lung cancer.

Buter J, Giaccone G.

Ann Oncol. 2005;16 Suppl 2:ii229-32. Review. No abstract available.

PMID:
15958463
2.

Histology matters: individualizing treatment in non-small cell lung cancer.

Neal JW.

Oncologist. 2010;15(1):3-5. doi: 10.1634/theoncologist.2009-0306. Epub 2010 Jan 19. No abstract available.

3.

Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.

Harichand-Herdt S, Ramalingam SS.

Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):217-23. doi: 10.1053/j.semtcvs.2008.09.005. Review.

PMID:
19038731
4.

Epidermal growth factor inhibition in solid tumours.

Ganti AK, Potti A.

Expert Opin Biol Ther. 2005 Sep;5(9):1165-74. Review.

PMID:
16120047
5.

Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?

Juergens R, Brahmer J.

Curr Oncol Rep. 2007 Jul;9(4):255-64. Review.

PMID:
17588349
6.

Gefitinib versus cetuximab in lung cancer: round one.

Minna JD, Peyton MJ, Gazdar AF.

J Natl Cancer Inst. 2005 Aug 17;97(16):1168-9. No abstract available.

PMID:
16106015
7.

Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.

Pirker R, Minar W, Filipits M.

Clin Lung Cancer. 2008;9 Suppl 3:S109-15. doi: 10.3816/CLC.2008.s.016. Review.

PMID:
19419924
8.

Newer opportunities in systemic therapy of lung cancer.

Rajan A, Gutierrez M, Giaccone G.

Ann Oncol. 2008 Sep;19 Suppl 7:vii31-7. doi: 10.1093/annonc/mdn445. No abstract available.

9.

Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?

Stinchcombe TE, Ramalingam SS.

Lancet Oncol. 2010 Jun;11(6):500-1. doi: 10.1016/S1470-2045(10)70120-0. Epub 2010 May 20. No abstract available.

PMID:
20493770
10.

Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.

Karamouzis MV, Grandis JR, Argiris A.

JAMA. 2007 Jul 4;298(1):70-82. Review.

PMID:
17609492
11.

[Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].

Lai RS, Xie L, Shen LS, He YM, Zhu CL.

Zhonghua Bing Li Xue Za Zhi. 2005 Nov;34(11):745-6. Chinese. No abstract available.

PMID:
16536324
12.
13.

Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).

Metro G, Finocchiaro G, Toschi L, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L, Cappuzzo F.

Rev Recent Clin Trials. 2006 Jan;1(1):1-13. Review.

PMID:
18393776
14.

EGFR pathway in advanced non-small cell lung cancer.

Merlo V, Longo M, Novello S, Scagliotti GV.

Front Biosci (Schol Ed). 2011 Jan 1;3:501-17. Review.

PMID:
21196393
15.

EGFR inhibition in NSCLC: the emerging role of cetuximab.

Herbst RS.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S41-51. Review.

PMID:
19780245
16.

Erlotinib-based perioperative adjuvant therapy for a case of unresectable stage IIIA (N2) nonsmall cell lung cancer.

Wang Q, Wang H, Li P, Zhu H, He C, Wei B, Ma J, Ma Z.

Am J Med Sci. 2010 Oct;340(4):321-5. doi: 10.1097/MAJ.0b013e3181e59ac2.

PMID:
20601859
17.

Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.

Dziadziuszko R, Jassem J.

Ann Oncol. 2012 Sep;23 Suppl 10:x193-6.

PMID:
22987961
18.

Clairvoyance or reliable prediction of the future?

van Zandwijk N, van de Vijver MJ.

Ann Oncol. 2007 Mar;18(3):407-8. No abstract available.

PMID:
17322538
19.

Investigational agents in the management of non-small cell lung cancer.

Pennell NA, Mekhail T.

Curr Oncol Rep. 2009 Jul;11(4):275-84. Review.

PMID:
19508832
20.

The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.

Comis RL.

Oncologist. 2005 Aug;10(7):467-70. Review. No abstract available.

Supplemental Content

Support Center